PART I . Overview We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular ...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001193125-26-084144 | EDGAR | 118K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029973 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022036 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005062 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002517 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009835 | EDGAR | — |
| 2020-02-26 | 2019-12-31 | 0001564590-20-006769 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001564590-19-005170 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001564590-18-004107 | EDGAR | — |
| 2017-02-28 | 2016-12-31 | 0001564590-17-002842 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269436 | EDGAR | 74K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-103971 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064412 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122239 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092720 | EDGAR | — |
| 2024-05-01 | 2024-03-31 | 0000950170-24-051234 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057414 | EDGAR | — |
| 2023-08-02 | 2023-06-30 | 0000950170-23-037125 | EDGAR | — |
| 2023-05-02 | 2023-03-31 | 0000950170-23-016654 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0000950170-22-021213 | EDGAR | — |
| 2022-08-02 | 2022-06-30 | 0000950170-22-013863 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007375 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-25 | 0001193125-26-072064 | EDGAR | 0K words |
| 2026-02-25 | 0001193125-26-071566 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010116 | EDGAR | — |
| 2025-12-19 | 0001193125-25-326969 | EDGAR | — |
| 2025-12-11 | 0001193125-25-315032 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310588 | EDGAR | — |
| 2025-11-03 | 0001193125-25-262591 | EDGAR | — |
| 2025-08-29 | 0001193125-25-192794 | EDGAR | — |
| 2025-08-21 | 0001193125-25-184625 | EDGAR | — |
| 2025-08-13 | 0001193125-25-179819 | EDGAR | — |
314 total filings indexed. 282 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000873303 |
| Ticker | SRPT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.sarepta.com |
| Listed | 1997-06-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report